Lamivudine Articles
Medeva Has Heavy Reliance On Hepagene
4 December 1998
Heptovir Approved In Canada
2 December 1998
AASLD Conference - Focus On HCV/HBV By Lehman
1 December 1998
BioChem Pharma Targeting Major Acquisition In USA
20 November 1998
Lamivudine Reverses Liver Disease In Hep B
11 November 1998
Adefovir Shows High Potency In Hepatitis B
11 November 1998
GW's Ziagen Endorsed By FDA Committee
3 November 1998
New Product Cycle For Glaxo Wellcome
28 October 1998
First Filings For GW's Amprenavir
20 October 1998
Date Set For Ziagen Review In USA
8 October 1998
Lamivudine Backed For Hep B Approval In USA
8 October 1998
First Phase III Data With GW's Agenerase
1 October 1998
Pharma Cost-Effectiveness: New ABPI Studies
25 September 1998
First Approval Of DuPont's Sustiva In USA
21 September 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
First Approval For Oral Hepatitis B Drug
20 August 1998
Healthy 2nd Qtr Sales/ Earnings At BioChem
5 August 1998
US Judge Stays Emory/ BioChem's Epivir Case
17 July 1998
First Data With USB's Lodenosine
9 July 1998
Abbott's ABT-378 in Phase III By Year End?
9 July 1998
Triangle Updates On Anti-HIV Portfolio
9 July 1998
GW's Abacavir Combo As Potent As PI Regimen
30 June 1998
Product News In Brief
25 June 1998
UK Pharma Leaders Outline Strategy
22 June 1998
PDL's HBV Antibody Enters Phase II
15 June 1998
New Drugs May Address HIV In Brain
15 June 1998
Two-Year Efficacy With Lamivudine In Hep B
26 May 1998
BioChem Begins Ph I BCH-10652 Trial
7 May 1998
BioChem Pharma To Increase Marketing Focus
6 May 1998
Lamivudine Efficacy In Hep B Shown In New Studies
20 April 1998
Gilead's Preveon Sees Success In HIV And Hep B
8 April 1998
GW Files First Dossier For Relenza
2 April 1998
GW's Combivir OKed In EU
19 March 1998
Glaxo Wellcome Profits Hit By Strength Of Sterling
19 February 1998
A Real Challenge To HIV With New Therapies?
12 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Promising Data With New GW Therapies
5 February 1998
P&U Suspends Rescriptor Trial
5 February 1998
DuPont Merck To File Sustiva NDA Soon
5 February 1998
B-MS' Stavudine "As Effective As" AZT
5 February 1998
1997 Net Income Up 139% At BioChem Pharma
5 February 1998
B-MS' Zerit Overtakes Glaxo's Zidovudine
30 January 1998
Agouron's Viracept OKed In Europe
29 January 1998
Global Anti-HIV Market To Top $5 Billion In 2005
21 January 1998
Israel OKs Extra Funding For New Drug Therapies
12 January 1998
Analysts Assess Outlook For US Drug Majors
8 January 1998
Remune Interim Data Due In 2Q98
11 December 1997
EU Approval Granted For Combivir
4 December 1997
UK Approves GW's Combivir
27 November 1997
Can Protease Inhibitor Resistance Be Combatted?
4 November 1997
Ph II Data With Vertex' 141W94
20 October 1997
Roche's Invirase Confers Survival Benefit
20 October 1997
Zerit/3TC More Effective Than AZT/3TC
20 October 1997
Combo Therapy With DuPont Merck's Sustiva
20 October 1997
New York Stock Comment
16 October 1997
Medeva's Hep B Vaccine; Protective And Therapeutic?
16 October 1997
Norvir Success In Pediatric HIV
16 October 1997
Long-Term Efficacy With Agouron's Viracept
15 October 1997
NDA Filed For New Soft-Gel Saquinavir
9 October 1997
GW's Combivir Approved In The USA For HIV
1 October 1997
HIV Undetectable With Crixivan Cocktail
17 September 1997
GW Files For Lamivudine Approval In China
27 August 1997
Underlying Growth Healthy At GW Despite Strong L
6 August 1997
Vertex And GW Begin Pediatric 141W94 Trial
17 July 1997
AIDS Study Terminated In Children
3 July 1997
Higher Biotech Earnings But Investors Stay Cool
19 May 1997
Progress In HIV Combination Therapy
19 May 1997
Investors Impressed With Glaxo Wellcome Pipeline
12 May 1997
Net Income Surges At BioChem Pharma
12 May 1997
Profits Soar At BioChem Pharma
5 May 1997
Promising Long-Term Data With Agouron's Viracept
21 April 1997
Lamivudine Improves Liver Histology In Hepatitis B
21 April 1997
Canadian Drug Price Comparisons "Unrealistic"
7 April 1997
New CPAC Approvals Include Two NCEs
7 April 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
BioChem Pharma Hits Profitability In 1996
14 March 1997
Indinavir-Based Regimen Cuts Mortality In AIDS
3 March 1997
Vertex And Glaxo Wellcome Begin Ph III With AIDS Therapy
24 February 1997
Remune Plus Drugs For HIV
24 February 1997
Can HIV Be Eliminated?
3 February 1997
No Resistance With Vertex' HIV Therapy?
3 February 1997
Promise With Agouron's Viracept & Roche's Invirase
3 February 1997
Triangle Reports Data On NNRTI For HIV
27 January 1997
Vertex HIV Protease Inhibitor In Phase II
20 January 1997
Spanish Health Care Spending On AIDS
13 January 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
HBV Resistance To Lamivudine
13 January 1997
Product News In 1996 Dominated By CNS
23 December 1996
BioChem Pharma Celebrates 10 Years
16 December 1996
BioChem Sees Profits In Third Quarter
25 November 1996
Extended Therapy "Better" Concludes Biochem's Lamivudine Trial
18 November 1996
BioChem Pharma Responds To Patent Infringement Accusation
21 October 1996
BioChem's Share Price Driven By Lamivudine
14 October 1996
New Hepatitis Treatments Highlighted At ICAAC
7 October 1996
New Data On Anti-HIV Drugs Presented
30 September 1996
Euro CPMP Plenary Meeting
23 September 1996
First Launch Of Boehringer Ingelheim's Nevirapine
2 September 1996
Epivir Launched In UK
2 September 1996
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
